Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average – Time to Sell?

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $15.49 and traded as low as $14.06. Seres Therapeutics shares last traded at $14.31, with a volume of 23,382 shares changing hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Seres Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $14.33.

Seres Therapeutics Price Performance

The stock has a market cap of $129.51 million, a price-to-earnings ratio of -4.01 and a beta of 0.22. The business’s 50 day moving average is $15.49 and its 200 day moving average is $16.88.

Institutional Trading of Seres Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in shares of Seres Therapeutics by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock valued at $1,282,000 after buying an additional 1,160 shares during the last quarter. Bank of America Corp DE grew its stake in Seres Therapeutics by 2,772.6% during the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock worth $103,000 after buying an additional 5,157 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in Seres Therapeutics during the fourth quarter worth approximately $213,000. Vontobel Holding Ltd. lifted its stake in Seres Therapeutics by 22.6% in the third quarter. Vontobel Holding Ltd. now owns 98,511 shares of the biotechnology company’s stock valued at $1,895,000 after buying an additional 18,186 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Seres Therapeutics by 6.8% in the third quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock valued at $6,001,000 after acquiring an additional 19,793 shares during the period. Institutional investors and hedge funds own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.